What’s Propelling Cytrx Corporation (NASDAQ:CYTR) After Higher Shorts Reported?

July 31, 2017 - By Ellis Scott

 What’s Propelling Cytrx Corporation (NASDAQ:CYTR) After Higher Shorts Reported?

Investors sentiment decreased to 1.38 in Q4 2016. Its down 0.47, from 1.85 in 2016Q3. It dropped, as 9 investors sold CytRx Corporation shares while 15 reduced holdings. 13 funds opened positions while 20 raised stakes. 24.13 million shares or 11.33% more from 21.67 million shares in 2016Q3 were reported.
Citigroup invested in 0% or 97,630 shares. Raymond James & Assoc has 0% invested in CytRx Corporation (NASDAQ:CYTR). 16,711 are held by Hsbc Public Ltd Com. Deutsche Bank & Trust Ag invested in 0% or 61,680 shares. Focused Wealth Mgmt Inc stated it has 8,800 shares or 0% of all its holdings. The California-based Wells Fargo And Co Mn has invested 0% in CytRx Corporation (NASDAQ:CYTR). Fincl Architects owns 800 shares. Schwab Charles Management has 0% invested in CytRx Corporation (NASDAQ:CYTR) for 126,000 shares. American Group Incorporated Inc accumulated 38,417 shares. Blackrock Fund Advsrs, a California-based fund reported 3.08M shares. Proshare Advsrs Lc invested 0% in CytRx Corporation (NASDAQ:CYTR). Sabby Mngmt Limited Liability owns 0.1% invested in CytRx Corporation (NASDAQ:CYTR) for 4.70M shares. Nationwide Fund Advisors holds 81,548 shares. Morgan Stanley invested in 0% or 397,752 shares. Kcg Holdg has invested 0% of its portfolio in CytRx Corporation (NASDAQ:CYTR).

The stock of Cytrx Corporation (NASDAQ:CYTR) registered an increase of 17.43% in short interest. CYTR’s total short interest was 22.42 million shares in July as published by FINRA. Its up 17.43% from 19.09M shares, reported previously. With 9.35 million shares average volume, it will take short sellers 2 days to cover their CYTR’s short positions. The short interest to Cytrx Corporation’s float is 21.37%.

The stock increased 17.87% or $0.146 during the last trading session, reaching $0.966. About 31.40M shares traded or 384.57% up from the average. CytRx Corporation (NASDAQ:CYTR) has declined 78.08% since July 31, 2016 and is downtrending. It has underperformed by 94.78% the S&P500.

CytRx Corporation is a biopharmaceutical research and development firm specializing in oncology. The company has market cap of $146.96 million. The Firm is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It currently has negative earnings. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma whose tumors have progressed after treatment with chemotherapy.

More news for CytRx Corporation (NASDAQ:CYTR) were recently published by: Seekingalpha.com, which released: “CytRx: SCLC Study Still Breathing?” on July 13, 2017. Prnewswire.com‘s article titled: “CytRx Corporation Announces Global Strategic License With NantCell Inc. For …” and published on July 28, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.